Drug Safety Initiative Is Topic Of CDER/DIA Webcast May 20
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Acting Director Galson and Drug Safety Oversight Board Executive Director Cummins are among the panelists. Topics will include IoM's drug safety study, the Drug Watch website, and an update on the search for the Office of Drug Safety's new director.
You may also be interested in...
FDA Rx Safety Website Will Include Drugs With Emerging Off-Label Issues
FDA's "Drug Watch" website will include safety information on drugs that have emerging safety signals for off-label uses
Drug Safety Oversight Board Will Require Two-Thirds Majority For Recommendations
FDA's Drug Safety Oversight Board will need a two-thirds majority of a quorum to make recommendations, a Center for Drug Evaluation & Research Manual of Policies & Procedures states
House Appropriations Subcommittee Plans FDA Hearing July 26
Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.